INT164416

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.64
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 5.17
Pain Relevance 1.02

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CDA) small molecule metabolic process (CDA) extracellular region (CDA)
Anatomy Link Frequency
cartilage 1
CDA (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 205 99.32 Very High Very High Very High
Osteoarthritis 10 91.92 High High
Thalamus 13 91.04 High High
Pain 4 80.12 Quite High
cytokine 1 75.00 Quite High
headache 1 67.84 Quite High
Angina 1 66.20 Quite High
Paracetamol 4 45.28 Quite Low
Inflammation 1 38.72 Quite Low
palliative 1 32.32 Quite Low
Disease Link Frequency Relevance Heat
Glioma 84 99.90 Very High Very High Very High
Lower Respiratory Tract Infection 81 99.88 Very High Very High Very High
Apoptosis 29 98.40 Very High Very High Very High
Disease 21 97.96 Very High Very High Very High
Pancreatic Cancer 4 97.40 Very High Very High Very High
Cancer 285 95.08 Very High Very High Very High
Osteoarthritis 11 91.92 High High
Non-small-cell Lung Cancer 35 86.96 High High
Communicable Diseases 3 84.84 Quite High
Toxicity 33 81.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Studies aimed at correlating CDA mRNA expression with outcome in gemcitabine-treated patients, particularly with pancreatic cancer, produced conflicting results.70,71 Similarly, most of the reports that have investigated the role of CDA polymorphisms in predicting gemcitabine activity failed to show any association with drug activity,72,73 although multiple findings seem to indicate that different CDA genetic variants might influence gemcitabine pharmacokinetics, with an ultimate impact on the toxicity of the compound.74,75
Gene_expression (expression) of CDA mRNA associated with toxicity and pancreatic cancer
1) Confidence 0.64 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886326 Disease Relevance 0.63 Pain Relevance 0
The CDA program (PROC CANDISC, SAS Institute, Cary, North Carolina, United States) constructed canonical covariance matrices between dependent variables (behavioral and CMRglc measures) across each of the four conditions, then performed an eigenvector decomposition (“factoring”) to produce normalized, orthogonal DFs such that:



Gene_expression (program) of CDA
2) Confidence 0.34 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1188239 Disease Relevance 0.12 Pain Relevance 0.05
Using functional categorization combined with gene ontology and a statistical analysis, five genes were found to be highly expressed in damaged cartilage (HBEGF, ASUS, CRLF1, LOX, CDA), whereas three genes were highly expressed in intact tissues (CHST2, PTPRD, CPAN6).
Gene_expression (expressed) of CDA in cartilage
3) Confidence 0.26 Published 2010 Journal Calcif. Tissue Int. Section Abstract Doc Link 19921088 Disease Relevance 0.80 Pain Relevance 0.40
Development of ARI case-detection algorithms (CDA) that use structured EMR parameters
Gene_expression (detection) of CDA associated with lower respiratory tract infection
4) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2954790 Disease Relevance 1.55 Pain Relevance 0.13
When these cells also expressed cytosine deaminase, additive killing was seen with combinations of both IFO and 5-FU [92].
Gene_expression (expressed) of cytosine deaminase
5) Confidence 0.09 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 1.00 Pain Relevance 0
Expression of the Cytosine Deaminase Transgene
Gene_expression (Expression) of Cytosine Deaminase
6) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2746284 Disease Relevance 0.06 Pain Relevance 0.16
This parental HB1.F3 cell line was further transduced retrovirally to stably express the E. coli cytosine deaminase gene (CD; EC 3.5.4.1), designated as HB1.F3.CD NSCs.
Gene_expression (express) of cytosine deaminase
7) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2746284 Disease Relevance 0.40 Pain Relevance 0.16
We assessed the ability of FE-Pro-labeled NSCs to target gliomas and express a therapeutic transgene (cytosine deaminase, CD) with in vitro Boyden chamber migration assays and immunohistochemistry, respectively.
Gene_expression (express) of cytosine deaminase associated with glioma
8) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2746284 Disease Relevance 0.60 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox